About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clareo Health | Ovarian Cancer Clinical Trials in Houston | 499 Studies

Clinical Trials Ovarian CancerHouston

Ovarian Cancer Clinical Trials in Houston

Find 499 clinical trials for ovarian cancer near Houston, Texas. Connect with research centers in your area.

All Ovarian Cancer trials nationwide All trials in Houston

Order

Status

RecruitingNot yet recruitingActive, not recruitingEnrolling by invitationCompletedTerminated

Phase

Early phase 1Phase 1Phase 1–2Phase 2Phase 2–3Phase 3Phase 4No phase

Who can join

Healthy volunteers too

Showing 81-100 of 499 trials

Active not recruitingTesting the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment TrialThis phase II ComboMATCH treatment trial compares selumetinib plus olaparib to selumetinib alone in women with endometrial or ovarian (fallopian tube and primary peritoneal)…NCT05554328·Birmingham, Alabama and 294 others

Ovarian Cancer Trials in Other Cities

New York Los Angeles Chicago Phoenix Philadelphia San Antonio

Data from ClinicalTrials.govTerms

CompletedPh 1 Trial of ADI-PEG 20 Plus Cisplatin in Patients With Metastatic MelanomaCertain cancers require the amino acid arginine. Arginine deiminase (ADI) is an enzyme from microbes that degrades arginine.NCT01665183·Houston, Texas and 1 other

CompletedA Study of the CD73 Inhibitor LY3475070 Alone or in Combination With Pembrolizumab in Participants With Advanced CancerThe reason for this study is to see if the CD73 inhibitor LY3475070 alone or in combination with pembrolizumab is safe and effective in participants with advanced cancer.NCT04148937·Denver, Colorado and 11 others

Active not recruitingGemcitabine Hydrochloride Alone or With M6620 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube CancerThis randomized phase II trial studies how well ATR kinase inhibitor M6620 (M6620) and gemcitabine hydrochloride work compared to standard treatment with gemcitabine hydrochloride…NCT02595892·Phoenix, Arizona and 16 others

UnknownA Diagnostic Test to Evaluate Cancer Risk Before Surgery in Women with an Ovarian MassOvarian cancer is a serious health risk with the highest death rate among gynecological cancers.NCT06566716·Chandler, Arizona and 7 others

RecruitingIACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid TumorsTo find the highest tolerable dose of IACS-6274 that can be given alone, in combination with bevacizumab and paclitaxel, or in combination with capivasertib to patients who have…NCT05039801·Houston, Texas

UnknownPaclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity CancerThis randomized phase III trial studies paclitaxel and carboplatin see how well they work compared with paclitaxel and ifosfamide in treating patients with fallopian tube, or…NCT00954174·Birmingham, Alabama and 537 others

CompletedA Phase 1/2, Open-Label, Dose-Escalation, Safety Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid TumorsThe purpose of this study is to determine the safety and tolerability and assess preliminary efficacy of INCAGN01949 in subjects with advanced or metastatic solid tumors.NCT02923349·New Brunswick, New Jersey and 7 others

CompletedPharmacokinetic and Safety Study of Niraparib With Normal or Moderate Hepatic Impairment PatientsNiraparib (Zejula®)is extensively metabolized and eliminated primarily by hepatic and renal pathways.NCT03359850·Los Angeles, California and 4 others

Active not recruitingSafety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLCThis is a First-in-Human Phase IA/IB/II open label dose escalation study of intravenous (IV) administration of ONC-392, a humanized anti-CTLA4 IgG1 monoclonal antibody, as single…NCT04140526·Springdale, Arkansas and 36 others

CompletedStudy of Oral PXD101 in Patients With Advanced Solid Tumors or LymphomaThis is a Phase I dose escalation study of PXD101 administered orally. Oral belinostat will be given once or twice daily at various dosing schedules to patients with solid tumors.NCT00413075·New Haven, Connecticut and 5 others

TerminatedABI-007 With Carboplatin as First-Line Therapy in Patients With Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube CarcinomaThe primary purpose of this study is to determine the maximum tolerated dose and dose-limiting toxicities (DLTs) of weekly and every 3-weeks ABI-007 in combination with…NCT00407407·Houston, Texas

CompletedMicroarray Analysis for Human Genetic DiseaseThis study will look at genetic changes which occur in the development of male and female breast cancer and other cancer.NCT00001898·Tucson, Arizona and 7 others

Active not recruitingBevacizumab in Ovarian Cancer Patients With Disease at Second-Look SurgeryThe goal of this clinical research study is to learn if Avastin (bevacizumab) can help to control ovarian, fallopian, or primary peritoneal cancer that has been found during…NCT02884648·Houston, Texas

CompletedPropranolol Hydrochloride and Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube CancerThis early phase I trial studies giving propranolol hydrochloride with standard chemotherapy in treating patients with ovarian, primary peritoneal, or fallopian tube cancer.NCT01504126·Gilbert, Arizona and 6 others

CompletedSafety Study of XL147 (SAR245408), in Combination With Paclitaxel and Carboplatin in Adults With Solid TumorsThe purpose of this study is to evaluate the safety and tolerability of XL147 in combination with paclitaxel and carboplatin in adults with solid tumors.NCT00756847·St Louis, Missouri and 3 others

RecruitingA Study of MT-4561 in Patients With Various Advanced Solid TumorsThis is a First In Human (FIH), multicenter, open-label, Phase I/II study to evaluate safety, tolerability, Pharmacokinetics (PK), pharmacodynamics, and efficacy of MT-4561 in…NCT06943521·Los Angeles, California and 5 others

CompletedStudy of Intermittent OSI-906 DosingMulticenter, open-label, phase 1, cohort dose escalation study to determine the maximum tolerated dose (MTD) of 3 intermittent OSI-906 dosing schedules.NCT00514306·Houston, Texas and 1 other

CompletedStudy of the Trifunctional Antibody Catumaxomab to Treat Recurrent Symptomatic Malignant AscitesThe purpose of this study is to determine whether the investigational drug catumaxomab is a safe and effective treatment for recurrent symptomatic malignant ascites.NCT00326885·Tucson, Arizona and 17 others

TerminatedFPA150 in Patients With Advanced Solid TumorsThis is a multi-center study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary efficacy of FPA150, an anti-B7H4 antibody alone or…NCT03514121·Scottsdale, Arizona and 17 others

PreviousPage 5 of 25Next

Other Conditions in Houston

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia